Sexually Transmitted Diseases

Hanneke Schuitemaker, PhD, explains the challenges faced when creating a vaccine for HIV.

Magda Opsomer, MD, shares the results of the Phase 3 EMERALD trial for darunavir.

Janssen Research & Development submits a new drug application for a darunavir-based once-daily, single-tablet regimen for the treatment of HIV in adults and adolescents 12 years and older.

Jessica Justman, MD, explains how decision makers can use the Population-based HIV Impact Assessment Project data.

In case you missed them, we've compiled the top 5 articles from this past week.

The transition from youth to adult HIV care is a critical juncture that provides opportunities for continued engagement if handled well. What role should adult care clinics play to maximize the number of adolescents who stay in treatment?

UCLA researchers have shown that using molecular methods to predict susceptibility testing could serve as a new way to monitor drug-resistant gonorrhea.

Researchers from the Moffitt Cancer Center find that the newest HPV vaccine protects against 9 cancer-causing strains of the virus.

A report released by the Wisconsin DOH shows a 58% increase in syphilis cases from 2015 to 2016.

The US government’s new plan comes on the heels of reports that 5 African countries are poised to gain complete control over their HIV epidemics.

Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Jessica Justman, MD, reveals the latest results of the Population-based HIV Impact Assessment Project (2017).

Administration of the HPV vaccine continues to lag behind that of other recommended vaccines. How can providers increase the proportion of adolescents vaccinated against this sexually transmitted virus?

A FDA expert advisory panel voted unanimously to back a new shingles vaccine developed by GlaxoSmithKline: Shingrix.

The New York State Department of Health warns of potential disease exposure in two facility locations in Westchester County.

A NIH network study finds that pre-exposure prophylaxis, approved for daily use in adults, can also reduce chances of HIV infection in young male adolescents.

In a new study on factors that make individuals susceptible to infectious diseases, researchers have found that cholesterol-lowering drugs may reduce susceptibility to certain diseases.

Although the number of fungal infections has fallen in the United States and other developed nations due to the ease of obtaining HIV testing and access to ART, the risk still exists.

Alex Rinehart, PhD, identifies the target population for cabotegravir.

Jessica Justman, MD, shares why the Population-based HIV Impact Assessment Project is so important.

NIH study sheds light on the mechanism behind increased cardiovascular risks for those living with HIV.

Stay up-to-date on the latest infectious disease news by checking out this snapshot of our top 5 articles of the week.

Living longer with HIV means that dying from cancer becomes more of a possibility.

Scientists from Northwestern Medicine use a novel approach to gain a better understanding of the HIV lifecycle.

Aetna, the third-largest insurer in the United States, inadvertently sent HIV-positive patients letters that revealed their HIV status through a large, clear window envelope.

A recent UNC study found that about one-third of HIV-positive patients with low viral loads chose to ignore federal guidelines to begin ART.

NIAID researchers make an unexpected discovery when examining how a cellular enzyme complex regulates herpesvirus; inhibiting the enzyme suppressed viral infection.

Proton pump inhibitors present risks to all patients, but those with HIV are especially advised to be cautious in using them.

Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.